Top Markets
#1 Bitway Bitway +55.02%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +41.19%
#3 Starpower Starpower +37.49%
#4 Pons Pons +34.50%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.80%
#6 aelf aelf +22.66%
#7 SkyAI SkyAI +19.87%
#8 Ocean Protocol Ocean Protocol +18.26%
#9 OpenEden OpenEden +18.13%
#10 Mubarak Mubarak +15.20%
Coin of the day
Bitway Bitway
Settings
Language
ENGLISH
Currency
USD
Theme
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
Rank in Stocks #29359
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Share Price
$0.365
Last synced: 2025-08-01
Market Cap
$21.54M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Elevation Oncology, Inc. (ELEV)

Category

Healthcare
Revenue for Elevation Oncology, Inc. (ELEV)
Revenue in Aug 2026 TTM: 0
According to Elevation Oncology, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Elevation Oncology, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH